摘要
目的:探讨在恶性肿瘤患者发热治疗中血必净的临床应用价值。方法:选取2010年1月至2013年1月间于我院诊断为恶性肿瘤伴发热患者130例,按其诊治顺序进行编号并随机分为对照组(65例)和观察组(65例),给予对照组患者芬必得口服治疗,给予观察组患者血必净注射液静点治疗,观察两组患者各临床观察指标,并进行统计学对比分析。结果:观察组治疗显效37例、有效21例、无效7例,治疗有效率为89.23%,对照组治疗显效23例、有效22例、无效20例,治疗有效率为69.23%,两组患者治疗有效率间差异明显,具有统计学意义(P<0.05);治疗过程中,对照组并发症发生率35.38%明显高于观察组并发症发生率3.08%,组间差异在统计学上有意义(P<0.05)。结论:在恶性肿瘤患者发热治疗中,血必净临床治疗疗效确切、显著,不良反应少,退热效果稳定。
Objective：To investigate the treatment of patients with malignant fever Xuebijing clinical value.Methods：Selected the patient who diagnosed as malignant fever 130 patients, their diagnosis and treatment are numbered sequentially and randomly divided into control group （65 cases） and observation group （65 cases）, administered to the control group of patients Fenbid oral therapy, blood will be given to the observation group were net injection intravenous therapy were observed indicators of clinical observation, and statistically analyzed.Results：The Observation group patients showed 37 cases, effective in 21 cases, 7 cases, the treatment rate was 89.23% in the control group therapy effective in 23 cases, effective in 22 cases, ineffective in 20 cases, the treatment rate was 69.23%, two groups of patients efficiently significant differences between, with statistical significance （P〈0.05）;treatment, control group 35.38%complication rate was significantly higher than the incidence of complications was observed 3.08%difference between the groups was statistically significant （P〈0.05）.Conclusion：In the treatment of patients with malignant fever, Xuebijing clinical efficacy, significantly fewer adverse reactions, fever effect is stable, it is worth popularization and application in clinical practice.
出处
《中国医药导刊》
2014年第3期486-487,共2页
Chinese Journal of Medicinal Guide
